{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Treatment of Hepatitis C Virus: An Update on Medications and Patient Education
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
This article has been approved by the Orthopaedic Nurses Certification Board for Category B credit toward recertification as an ONC.Purpose of Activity
To provide information on direct-acting antiviral (DAA) medications to treat infection from the hepatitis C virus (HCV).Learning Objectives
After completing this continuing education activity you will be able to:
- Recognize risks and adverse effects commonly associated with DAA for HCV treatment.
- Outline issues related to the use of DAA, including the dosing and administration of the drugs.
Disclosures
The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.
Price:
$15.00
Credits:
- ANCC 1.5 CH / 1.5 APH
- DC - BON 1.5 CH
- KY-BON 1.5 CH
- GA - BON 1.5 CH
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
Awarded Advanced Pharmacology Hours (APH)
Awarded Advanced Pharmacology Hours (APH)
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: ON0719C
Published: Jul/Aug 2019
Expires: 12/31/2026
Sources:
Orthopaedic Nursing
Required Passing Score: 14/20 (70%)
Specialties:
Infectious Diseases
Topics:
Hepatitis C